A new medical application for nitric oxide [ Return towards  Health  ]

The Group has developed a new nitric oxide application to treat pulmonary arterial hypertension. In 2008, the Group was granted market authorization for VASOKINOX.

Pulmonary arterial hypertension (PAH) is a pathology characterized by abnormally high arterial pressure. There are many signs: the patient can notably feel out of breath after making a physical effort, have thoracic pain, abnormal fatigue, palpitations, etc.

It is a serious ailment that leads to heart failure. In the long term and without treatment, it may even bring about the patient’s death. Treatments exist but they are of limited effectiveness. PAH can be checked by the administration of vasodilators, medicines that dilate blood vessels and improve blood oxygenation.

VASOKINOX, developed by Air Liquide, is an innovative medication, mainly composed of  nitrogen monoxyde, a gas naturally produced by the arterial cells. This gas immediately acts on the lungs' ventilated zones and enables PAH to be effectively treated. In 2008, Air Liquide received the market approval for this medication prescribed to treat PAH that occurs during or after heart surgery in both adult and child.

Air Liquide engineers have also developed OPTIKINOX, a mobile station for administering appropriate doses of VASOKINOX into the patient’s respiratory system.

Company

Contact

For any further information, contact us:

  • By mail :

Nathalie Simon de Kergunic

1 Chemin de la Porte des Loges

Les Loges en Josas

BP 126 - 78350 Jouy en Josas - France

Please, fill the form

Click Here